Read the article in The Wall Street Journal: U.S. Biotechs Are Keeping More Secrets to Beat Copycats in China

In our strategy and CI work with biopharma leaders, no topic comes up more than China. Earlier this year we published a report mapping 18K+ Chinese drug programs and $18B in deal volume - it's clear that China has arrived on the global stage.

One pattern that stood out: in the ~12-18 months after a major Western catalyst, fast-follower assets from Chinese companies explode. Every biopharma company now needs a China strategy, especially for positioning programs against these fast followers. This is the exact type of work Sleuth supports.

Excited to have worked with Xavier Martinez and The Wall Street Journal to feature Sleuth data to help bring that fast follower story to life.